Real time visualization of cellular events by Live Cell Imaging (LCI) has led to a better understanding of the global dynamic biological process. In a constantly evolving field, tebu-bio regularly introduces innovative tools, such as this selection of 5 new LCI probes.

Gene knock-out, which is gene editing leading to loss of function, just requires delivering into cells the 2 CRISPR system actors: the CAS9 endonuclease and the specific guide RNA to target the gene of interest. Thus, simple transfection of CleanCap CAS9 mRNA and gRNA followed by cell isolation with the smart aliquotor is a convenient and robust method. Howevery, what can you do if the cells are hard-to-transfect?

While Raybiotech recently released their 2000 target antibody array, a publication from “The Scientist” highlighted the benefit of these High-density multiplexed technology in biomarker discovery. As a perfect complement to traditional techniques like Mass Spectrometry, these antibody arrays provide an interesting alternative for low abundance targets, with a sensitive and high throughput approach. tebu-bio laboratories has been appointed by RayBiotech as one of the 3 companies worldwide to perform contract research on these arrays, and can take your project on board from sample processing to data analysis. This post summarizes the services available, from protein profiling, to phosphorylation and glycosylation studies, including biostatistics support. It’s worth noting that all the arrays listed are compatible with most laser scanners and can be processed in any lab.

In new drug development pipelines, there is an increasing trend to switch from “small” to “large” molecules (also known as biologics). While the FDA guidance was quite specific with their recommendations for small molecules ADME-Tox studies, there is not much currently published for these large molecules.

The Japanese PDMA guidelines 2019 issue refers to some specificity regarding their internalization and degradation pathway. They are also well known to be prone to trigger cytokine release. The so called “cytokine storm” is one of the major toxicity events to be feared.

To support R&D projects around Biologics development, I have illustrated in this post what tebu-bio can offer in terms of reagents and services, including tools to monitor cytokine release (blood derivatives and cytokine multiplex assays), and reagents to help decipher their mechanism of action and catabolism.